Link
Microlearning Video Series: Risk Communication and COVID-19 Vaccines
Organization: Training Programs in Epidemiology and Public Health Interventions Network (TEPHINET)Published: 2022
"The U.S. Centers for Disease Control and Prevention (CDC), and other partners, TEPHINET developed a series of microlearning videos to provide “quick learns” for those wanting to better understand and use effective risk communication principles and best practices in their daily work. These videos were developed to address the COVID-19 pandemic, with a focus on COVID-19 vaccines and risk communication." - Training Programs in Epidemiology and Public Health Interventions Network
Resource Group:
Implementation Tool
Product Type: Learning Module
Outbreak and Crisis Management
Crisis Communication
Professional Development
Education and Training
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Product Type: Learning Module
Category:
Program Planning and Delivery,Outbreak and Crisis Management,Crisis Communication,Professional Development,Education and Training,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Program Planning and DeliveryOutbreak and Crisis Management
Crisis Communication
Professional Development
Education and Training
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Audience:
Health Care Professional
Region: United States
Region: United States
Language:
English
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.